ABT Stock: BTIG Cuts Price Target but Holds Buy as Abbott Trades Near 52-Week Low

April 1, 2026

By TrendSpider Editor

ABT Stock: BTIG Cuts Price Target but Holds Buy as Abbott Trades Near 52-Week Low

BTIG analyst Marie Thibault reaffirmed a Buy rating on Abbott Laboratories but trimmed her price target from $140 to $131, a move that comes as ABT shares sit under significant pressure near their 52-week floor. Abbott is currently trading at $103.32, up 0.71% on the session, but still uncomfortably close to its 52-week low of $100.875 and well off the 52-week high of $139.05. The reduced price target suggests even a bullish analyst sees a more cautious near-term path for the medical devices and diagnostics giant.

Key Drivers of the ABT Stock Move

Main Catalyst: BTIG's Marie Thibault confirmed a Buy rating on ABT while lowering the price target by $9, from $140 to $131. The confirmation of the Buy stance provides a degree of support, but the target reduction signals that the firm has moderated its near-term expectations for the stock.
Bull Case: Despite the trim, the revised $131 price target still implies roughly 26.8% upside from the current price of $103.32. The reaffirmation of the Buy rating from a named analyst at a recognized firm provides a credibility floor and suggests the selloff may be creating a value opportunity for patient investors.
Bear Case: ABT is trading just $2.45 above its 52-week low of $100.875, a precarious position technically. The $9 reduction in BTIG's price target reflects a meaningful downward revision in fundamental expectations, and the gap between the current price and the prior $140 target highlights how far sentiment has deteriorated over the past year.

Abbott finds itself at a critical technical juncture heading into the spring. Trading this close to a 52-week low, the stock is drawing scrutiny from both value-oriented buyers looking for a reversion and momentum traders watching for a potential breakdown below the $100.875 floor. The BTIG action is the lone analyst rating in the current data, and with an average price target of $131 reflecting that single estimate, the implied upside remains substantial on paper. Whether ABT can build on today's modest 0.71% gain and stabilize above the $100 level will be a key test of near-term conviction. Investors will want to monitor upcoming earnings and any updates on Abbott's diagnostics and medical device segments, which have historically been the primary drivers of analyst estimate revisions for the company.

ABT Analyst Ratings and Price Targets

BTIG analyst Marie Thibault issued the sole rating action in the current period, confirming a Buy rating on Abbott Laboratories while reducing the price target to $131 from a prior $140. The $9 target cut represents a 6.4% reduction in BTIG's stated upside expectation. The current average price target based on available data stands at $131. There were no upgrades or downgrades associated with this action, only a target revision alongside a rating confirmation.

ABT Seasonality

The early April window historically precedes Abbott's first-quarter earnings release, a period that tends to bring elevated volatility and analyst positioning activity as the street resets estimates ahead of results. Rating confirmations and price target adjustments in late March through early April are common as analysts finalize their models going into earnings season.

ABT Relative Performance

Abbott's current price of $103.32 represents a position just 2.4% above its 52-week low of $100.875, while the 52-week high of $139.05 sits roughly 34.6% above current levels. Today's session gain of 0.71% offers a modest reprieve, but the stock's proximity to its annual floor underscores that ABT has meaningfully underperformed the broader market over the trailing 52-week period, a trend that will need to reverse for the BTIG bull case to play out.